Welcome to our dedicated page for Gossamer Bio SEC filings (Ticker: GOSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Gossamer Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Gossamer Bio's regulatory disclosures and financial reporting.
Gossamer Bio, Inc. received a notice from Nasdaq that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days from February 24 through April 7, 2026. This puts its listing on the Nasdaq Global Select Market at risk.
The company has 180 days, until October 5, 2026, to regain compliance by having its closing bid at or above $1.00 for at least ten consecutive business days. If it still does not comply, it may seek an additional 180-day period by transferring to the Nasdaq Capital Market and potentially taking actions such as a reverse stock split. The company plans to monitor its share price and evaluate options, but there is no assurance it will maintain its Nasdaq listing.
Gossamer Bio Inc Schedule 13G/A (Amendment No. 6) reports that The Vanguard Group holds 0 shares of Common Stock and beneficial ownership of 0% of the class as disclosed. The filing explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or divisions to report holdings separately.
Gossamer Bio, Inc. ownership disclosure: 683 Capital Partners, LP beneficially owned 5,000,000 shares of Common Stock and warrants exercisable for 4,331,304 shares. The reporting group may be deemed to beneficially own these amounts through 683 Capital Management, LLC and Ari Zweiman. The filing states this position represents approximately 3.90% of the company on an as‑adjusted basis, using 234,696,281 shares outstanding as of March 10, 2026 and including the currently exercisable warrants. The Reporting Persons report shared voting and dispositive power over the listed securities.
Gossamer Bio, Inc. reported that Chief Medical Officer Richard Aranda had a one-time repricing of certain outstanding stock options effective March 19, 2026. A series of existing options were surrendered back to the company and replaced with new options covering the same numbers of shares, but with a reduced exercise price of $0.45 per share.
According to the disclosure, all other terms and conditions of the repriced options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on his ongoing service with the company.
Gossamer Bio, Inc. executive Caryn Peterson, EVP of Regulatory Affairs, reported a one-time repricing of multiple stock option awards effective March 19, 2026. Previously granted options were surrendered back to the company and replacement options for the same share amounts were granted with a reduced exercise price of $0.45 per share. According to the disclosure, all other terms of these options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on her ongoing service.
Gossamer Bio Chief Commercial Officer option repricing: Gossamer Bio, Inc. adjusted stock option awards held by Chief Commercial Officer Robert Paul Smith Jr. Effective as of March 19, 2026, the company approved a one-time repricing of certain outstanding options, lowering their exercise price to $0.45 per share while keeping vesting schedules and terms unchanged. Two existing option grants for 562,500 and 572,000 shares of common stock were disposed of back to the issuer at prior exercise prices of $2.88 and $1.13 per share, and replacement options for the same respective share amounts were granted at the new $0.45 exercise price under the 2019 Incentive Award Plan.
Gossamer Bio, Inc. reported that President & CEO Faheem Hasnain had several existing stock option awards surrendered to the company and replaced as part of a one-time repricing effective on March 19, 2026. The repricing reduced the exercise price of each affected option grant to $0.45 per share while keeping all other terms, including vesting schedules and expiration dates, unchanged under the company’s 2019 Incentive Award Plan. Individual grants include, for example, 1,680,000 stock options now exercisable at $0.45 per share expiring in 2036. These are compensation-related derivative transactions rather than open-market share purchases or sales.
Gossamer Bio, Inc. reported that COO/CFO Bryan Giraudo had several existing stock option awards canceled and reissued as part of a one-time option repricing under the company’s 2019 Incentive Award Plan.
The repricing, effective March 19, 2026, reduced the exercise price of these options to $0.45 per share from prior exercise prices ranging from $0.838 to $2.88, while keeping all other terms, including vesting schedules and option terms, unchanged. These are compensation-related derivative transactions and do not involve open-market purchases or sales of common stock.
Gossamer Bio EVP Christian Waage reported a one-time stock option repricing and related option grants and cancellations. Effective as of March 19, 2026, the company approved an option repricing that reduced the exercise price of certain outstanding options to $0.45 per share under its 2019 Incentive Award Plan.
On that date, Waage received multiple new stock option awards with an exercise price of $0.45 covering an aggregate of 2,065,584 shares of common stock, while an equal number of higher-priced options with exercise prices ranging from $0.838 to $2.88 per share were surrendered to the issuer.
All other terms of the repriced options, including vesting schedules and expiration dates through 2036, remain in effect and continue to be tied to Waage’s ongoing service with Gossamer Bio.